“Cirrhosis Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Cirrhosis Market.
The Cirrhosis Pipeline report embraces in-depth commercial, regulatory, and Cirrhosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Cirrhosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for Cirrhosis treatment and the aggregate therapies developed by major pharma companies.
-
It accesses the different Cirrhosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the major Cirrhosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the Cirrhosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Cirrhosis therapeutic market.
Cirrhosis Therapeutics Landscape
There are approx. 50+ key companies developing therapies for Cirrhosis. Currently, Galectin Therapeutics is leading the therapeutics market with its Cirrhosis drug candidates in the most advanced stage of clinical development.
Cirrhosis Companies Actively Working in the Therapeutic Market Include:
-
GWOXI Stem Cell Applied Technology
-
Lipocine
-
Galectin Therapeutics
-
Pharmicell Co., Ltd.
-
BioVie
-
Ocera Therapeutics
-
Gilead Sciences
-
Chia Tai Tianqing Pharmaceutical Group
-
Zydus Cadila
-
Novartis Pharmaceuticals
-
Genfit
-
PRISM Pharma Co
-
Bristol-Myers Squibb
-
COUR Pharmaceutical Development Company, Inc.
-
HighTide Biopharma
-
Gannex Pharma Co., Ltd.
And Many Others
Emerging and Marketed Cirrhosis Drugs Covered in the Report Include:
-
GXHPC 1: GWOXI Stem Cell Applied Technology
-
LPCN 1148: Lipocine
-
Belapectin: Galectin Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Cirrhosis Companies Working in the Market @
https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight
Analysis of Emerging Cirrhosis Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued and inactive candidates
Route of Administration
The Cirrhosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intra-articular
-
Intraocular
-
Intrathecal
-
Intravenous
-
Ophthalmic
-
Oral
-
Parenteral
-
Subcutaneous
-
Topical
-
Transdermal
Molecule Type
Products have been categorized under various Molecule types such as
-
Oligonucleotide
-
Peptide
-
Small molecule
Learn How the Cirrhosis Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @
https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Cirrhosis Treatment Patterns
4. Cirrhosis – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Cirrhosis Late Stage Products (Phase-III)
7. Cirrhosis Mid-Stage Products (Phase-II)
8. Cirrhosis Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Cirrhosis Discontinued Products
13. Cirrhosis Product Profiles
14. Major Cirrhosis Companies in the Market
15. Key Products in the Cirrhosis Therapeutics Segment
16. Dormant and Discontinued Products
17. Cirrhosis Unmet Needs
18. Cirrhosis Future Perspectives
19. Cirrhosis Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/cirrhosis-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports By DelveInsight
“Hepatitis A Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Hepatitis A market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Hepatitis A market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/